Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 464

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 464
---
 and commercialization activities or future collaborations. The issuance of New OSR Holdings’ common shares and the PIPE Financing may adversely affect the market price of New OSR Holdings Common Stock. Cash Flows The following table summarizes OSR Holdings’ cash flow data for the periods indicated (in thousands):

|                                                      |     | Year Ended December 31, 
      (KRW in thousands) 
                    2022 |   |     |       2023 |   |
|:-----------------------------------------------------|:----|------------------------:|:--|:----|-----------:|:--|
| Net cash used in operating activities                |     |                (652,051 | ) |     | (7,100,008 | ) |
| Net cash provided by (used in) investing activities  |     |              (2,161,262 | ) |     |     28,210 |   |
| Net cash provided by (used in) financing activities  |     |               5,955,339 |   |     |  4,163,034 |   |
| Net increase (decrease) in cash and cash equivalents |     |               3,142,026 |   |     | (2,908,764 | ) |

Contractual Obligations and Commitments OSR Holdings and its subsidiaries have entered into various contractual arrangements that involve future payments, such as on leases, clinical trials, other R&D activities and minimum purchases of medical devices (for resale). New OSR Holdings’ obligations for those payments in 2024, which vary in time and amount, are currently expected to be approximately KRW 7.55 billion. Those contracts for which the amount payable pursuant to the contract exceeds 5.0% of OSR Holdings revenues are described in the following table.

| Name of Party       |     |        Amounts Due 
 (KRW in thousands) |     | Due Dates |     | Termination date |     | Description and Material terms                                                            |
| Biotoxtech          |     |            800,000 |     | N/A       |     | 12/31/2025       |     | Pre-clinical studies of DRT – 101; payment schedule varies on clinical progress           |
| Microport Neurotech |     |          1,360,000 |     | N/A       |     | 12/31/2025       |     | Distribution agreement; Payment schedule varies on order (60 days after invoice issuance) |

The